<DOC>
	<DOCNO>NCT02268201</DOCNO>
	<brief_summary>KTx recipient receive cyclosporine-based immunosuppressive therapy , opinion investigator would benefit switch tacrolimus-based immunosuppression , switch immunosuppressive therapy tacrolimus-based one . Efficacy safety patient observe 52 week .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Kidney Transplant Recipients When Changed From Cyclosporine Tacrolimus Prolonged-release Capsule Tacrolimus Capsule</brief_title>
	<detailed_description>The primary objective study compare adherence kidney transplant recipient treat Prograf Advagraf regimens . The secondary objective study : - To compare renal function ( eGFR ) KTx recipient treat Cyclosporine Tacrolimus regimens . - To compare QoL KTx recipient treat Cyclosporine Tacrolimus regimens . - To compare efficacy Cyclosporine Tacrolimus regimens KTx recipient . - To compare safety Cyclosporine Tacrolimus regimens KTx recipient .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Patients receive cyclosporinebased immunosuppressive therapy 6 months， maintain stable regimen least 8 week enrollment The trough blood level cyclosporine maintain 50200ng/ml least 4 week enrollment SCr &lt; 200 μmol/l ( 2.3 mg/dl ) Females childbearing potential must negative pregnancy test within 48 hrs prior randomization reliable method contraception start 4 week prior whole study Understand sign approve informed consent form Patients solid organ transplantation 24 hour proteinuria &gt; 2g SGPT/ALT，SGOT/AST total bilirubin rise double normal level Patients suffer serious infection lesion Patients severe diarrhea vomiting , peptic ulcer and/or defective absorption Patients severe heart , lung disease , abnormal glucose tolerance malignant tumor history Known contraindication administration Tacrolimus . Subject known hypersensitivity tacrolimus , product excipients Pregnancy lactate woman Patients participate another clinical trial past month Patient refuse sign informed consent form Patient willing continue study want withdraw study Poor adherence lose followup Violation protocol Severe adverse event occur need withdraw study accord investigator 's judgment Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>immunosuppressive therapy</keyword>
	<keyword>tacrolimus</keyword>
</DOC>